glp 1 shot tirzepatide Compounded (GLP-1/GIP) Tirzepatide

References: Drucker, D

PubMed 35

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on formulation and dose) Vomiting (524% of patients) Diarrhea (830% of patients) Abdominal pain (511% of patients) Constipation (324% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish over time as physiological tolerance develops

lkenizdeki kurallar da biliyoruz

The drug name is downstream of those answers

This is not semaglutide damages the retina so much as fast improvement can transiently worsen retinopathy in higher risk patients, which has parallels in insulin intensification